SEC Form 4 · accession 0000907654-26-000073
Oruka Therapeutics, Inc. · ORKA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Joana Goncalves
Officer — Chief Medical Officer
Period of report
Jul 15, 2026
Accepted (ET)
Jul 15, 2026 · 7:36 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0000907654
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jul 15, 2026 | M | 3,500 | $6.84 | A | 36,218 | D | |
| Common Stock | Jul 15, 2026 | M | 3,500 | $7.80 | A | 39,718 | D | |
| Common StockF2 | Jul 15, 2026 | S | 400 | $84.365 | D | 39,318 | D | |
| Common StockF3 | Jul 15, 2026 | S | 2,497 | $85.8572 | D | 36,821 | D | |
| Common StockF4 | Jul 15, 2026 | S | 3,803 | $86.6764 | D | 33,018 | D | |
| Common StockF5 | Jul 15, 2026 | S | 300 | $87.2533 | D | 32,718 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (right to buy)F6 | $6.84 | Jul 15, 2026 | M | 3,500 | D | — | May 6, 2034 | Common Stock | 3,500 | 200,563 | D |
| Employee Warrant (right to buy)F7 | $7.80 | Jul 15, 2026 | M | 3,500 | D | — | Jul 14, 2034 | Common Stock | 3,500 | 171,992 | D |
Explanation of responses
- F1These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on September 19, 2025.
- F2The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $83.87 to $84.57, inclusive. The reporting person undertakes to provide to Oruka Therapeutics, Inc., any security holder of Oruka Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4) and (5) to this Form 4.
- F3The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $85.21 to $86.20, inclusive.
- F4The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $86.21 to $87.04, inclusive.
- F5The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $87.25 to $87.26, inclusive.
- F6The option vests as to 1/4 of the underlying shares on April 18, 2025 and as to 1/48 of the underlying shares monthly from April 18, 2025.
- F7The warrant vests as to 1/4 of the underlying shares on April 18, 2025 and as to 1/48 of the underlying shares monthly from April 18, 2025.